Platelet derived small extracellular vesicles are cardioprotective in murine myocardial infarction

Technical Summary: Platelet-Derived Small Extracellular Vesicles are Cardioprotective in Murine Myocardial Infarction

Problem Statement
Ischaemic heart disease and myocardial infarction (MI) remain the leading causes of global mortality. While survival rates for the initial ischemic event are high, the subsequent loss of cardiomyocytes—which have extremely low replication rates—leads to permanent muscle loss, replacement with non-contractile fibrotic scar tissue, and the progression to heart failure. Current clinical treatments primarily alleviate symptoms or reduce cardiac strain (e.g., β-blockers, ACE inhibitors) rather than promoting direct myocardial repair. Although platelets are known to mediate primary ischemic damage via thrombus formation, they also release a complex secretome containing soluble factors and extracellular vesicles (EVs) that may possess pro-reparative properties. However, the specific cardioprotective efficacy of these platelet-derived components, distinct from their thrombotic risks, remains underexplored as a therapeutic strategy.

Methodology
The study utilized a murine model of permanent coronary artery ligation (left anterior descending artery) to induce MI. The experimental workflow involved the following steps:

1. Platelet Isolation and Stimulation: Washed platelets were isolated from C57BL/6 mice and stimulated ex vivo using collagen-related peptide (CRP-A) to trigger secretion.
2. Secretome Fractionation: The resulting platelet releasate was segregated into three distinct fractions via differential centrifugation:
   • Full Releasate: The total secretome.
   • Molecular Releasate: The supernatant depleted of all EVs, containing soluble granular content.
   • Extracellular Vesicles (EVs): Separated by size into Small EVs (<100 nm) and Large EVs (>100 nm), adhering to recent ISEV characterization guidelines.
3. In Vivo Administration: Immediately following LAD ligation, mice were injected intramyocardially with either the full releasate, isolated fractions (Small EVs, Large EVs, or Molecular Releasate), or a vehicle control.
4. Characterization: EV fractions were validated using Dynamic Light Scattering (DLS) for size distribution and Transmission Electron Microscopy (TEM) for structural integrity.
5. Functional and Histological Assessment: Cardiac function was monitored via echocardiography (Ejection Fraction, Fractional Shortening, ventricular dimensions) at 1, 2, and 3 weeks post-MI. Histological analysis at 21 days included Masson's trichrome staining for collagen deposition (fibrosis) and immunofluorescence for α-smooth muscle actin (ACTA2) to assess vascular density.

Key Results

• Functional Recovery: Injection of the full platelet releasate significantly improved cardiac function compared to vehicle controls, evidenced by higher Ejection Fraction (EF) and Fractional Shortening (FS) from day 7 to day 21.
• Role of Small EVs: The cardioprotective effect was predominantly mediated by the Small EV fraction. Mice treated with isolated Small EVs showed functional recovery (EF and FS) and reduced ventricular dilation comparable to the full releasate. In contrast, Large EVs had no significant effect on functional recovery, and the Molecular Releasate showed only a non-significant intermediate trend.
• Fibrosis Reduction: Treatment with the full releasate significantly reduced left ventricular collagen deposition compared to controls. Small EVs also demonstrated a trend toward reduced fibrosis, though the full releasate appeared most effective, suggesting potential additive effects of multiple components. A notable sex-dependent effect was observed, with male mice exhibiting significantly higher baseline fibrosis than females; however, treatments generally reduced fibrosis in males.
• Vascularization: All isolated components increased vessel density 21 days post-MI, but only the Small EV treatment resulted in a statistically significant increase in vascular density and vessel number compared to controls.
• Early Mechanisms: Analysis of apoptosis and autophagy at 3 hours post-MI revealed no significant effects, suggesting the therapeutic benefits manifest through later regenerative processes rather than immediate cytoprotection.

Significance and Claims
The study establishes platelet-derived small extracellular vesicles as promising therapeutic candidates for MI. The authors claim that these vesicles harness the endogenous regenerative potential of platelets while isolating them from the thrombotic risks associated with whole platelet administration.

Key claims regarding the significance of the findings include:

• Dual Role of Platelets: The findings support the hypothesis that platelets play a dual role in MI pathology—initiating infarction via thrombosis but also coordinating recovery via "thromborepair" mechanisms mediated by their secretome.
• Therapeutic Potency: Platelet-derived Small EVs demonstrated high therapeutic potency. In this study, a single dose of 1.4 µg of platelet Small EVs increased Ejection Fraction by approximately 15–24% at 1, 2, and 3 weeks post-MI. The authors note this efficacy is comparable to or exceeds results seen in meta-analyses of stem cell-derived EVs, which typically utilize much higher doses (median 100 µg) and report lower EF improvements.
• Clinical Translation Potential: Due to their low immunogenicity, low toxicity, and ability to be stored (frozen or lyophilized), platelet-derived Small EVs represent a viable cell-free therapeutic approach to minimize ischemic injury and promote tissue repair, potentially reducing the burden of post-MI heart failure.

The paper concludes that while further research is needed regarding long-term safety and optimal dosing, platelet-derived Small EVs offer a novel avenue for addressing the growing clinical burden of heart failure by promoting cardiac functional repair and revascularization.